menu
    • menu
    [{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"Carnitine O-palmitoyltransferase 1, muscle isoform; Xanthine dehydrogenase\/oxidase; Liver carboxylesterase 1; Myeloperoxidase; Carnitine O-palmitoyltransferase 1, liver isoform; Solute carrier family 22 member 4; Organic cation\/carnitine transporter 2; Carnitine O-acetyltransferase; Mitochondrial basic amino acids transporter; Mitochondrial carnitine\/acylcarnitine carrier protein; Peroxisomal carnitine O-octanoyltransferase; Carnitine O-palmitoyltransferase 2, mitochondrial","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"CRAT","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"CRAT","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Cardispan

    Menu

    Cardispan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            American Regent

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, "AP" Rated, and Therapeutically Equival...

                            Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.

                            Product Name : Carnitor-Generic

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            October 10, 2023

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP

                            Details : ANI’s Levocarnitine Tablets are the generic version of the Reference Listed Drug (RLD) Carnitor®. The launch of Levocarnitine Tablets is another example of ANI’s commitment to increasing patient access to affordable, high-quality medicines.

                            Product Name : Levocarnitine-Generic

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            December 19, 2022

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lo.Li.Pharma

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Lo.Li.Pharma

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyperthyroidism: Methimazole Plus L-carnitine and Selenium

                            Details : L-Carnitine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperthyroidism.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2021

                            Lead Product(s) : Levocarnitine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth